Abstract:Background: The proatherogenic effect of LDL cholesterol and antiatherogenic effect of HDL cholesterol have been confirmed in general population. But controversy arises on the protective role of HDL cholesterol and predictive superiority of apolipoprotein (apo)B among CAD patients. Objectives: This study was to identify the association of different lipid measurements with CAD prognosis and compare their prognostic significance. Methods: The study cohort included 1916 CAD patients who were 40-85 years of age. Cox proportional hazards regression models were used to estimate the association of baseline 6 lipid factors (HDL cholesterol, LDL cholesterol, total cholesterol, non-HDL cholesterol, apoA-I, and apoB) and 3 ratios with all-cause and CVD mortality. Results: During a median follow-up of 3.1 years, 147 deaths were recorded, 113 of which were due to CVD. When lipid factors were categorized, HDL cholesterol showed a U-shape association with all-cause and CVD mortality after adjustment for major CVD risk factors. The multivariable-adjusted hazard ratios in HDL cholesterol<40 mg/dL and ≥70 mg/dL groups were 2.09 (95% CI 1.37-3.20) and 3.06 (95% CI 1.08-8.70) for all-cause mortality, and 2.59 (95% CI 1.53-4.38) and 4.83 (95% CI 1.47-15.8) for CVD mortality, compared with HDL cholesterol between 40 and 49 mg/dL group. ApoA-I level was inversely associated with the risk of all-cause and CVD mortality. The multivariable-adjusted hazard ratios across quartiles of apoA-I were 1.00, 0.59 (95% CI 0.38-0.92), 0.43 (95% CI 0.26-0.70), and 0.56 (95% CI 0.35-0.88) for all-cause mortality (P for trend =0.004), and 1.00, 0.55 (95% CI 0.33-0.91), 0.39 (95% CI 0.22-0.70), and 0.57 (95% CI 0.34-0.95) for CVD mortality (P=0.007). Serum LDL cholesterol, apoB, LDL/HDL ratio, and apoB/apoA-I ratio were positively associated with the risk of CVD mortality. Patients with LDL cholesterol ≥190 mg/dL had a 4.35-fold risk of CVD mortality (95% CI 1.34-14.2) compared with patients with LDL cholesterol<70 mg/dL. Patients with apoB ≥110 mg/dL had a 2.06-fold risk of CVD mortality (95% CI 1.10-3.85) compared with patients with apoB<90 mg/dL. The multivariable-adjusted hazard ratios in highest quartiles of LDL/HDL ratio and apoB/apoA-I ratio were 1.61 (95% CI 1.01-2.56) and 2.00 (95% CI 1.21-3.31) for all-cause mortality, and 1.74 (95% CI 1.02-2.96) and 2.33 (95% CI 1.32-4.14) for CVD mortality compared with the lowest quartiles. After further pair-wise comparison, LDL/HDL ratio and LDL cholesterol had stronger associations with all-cause and CVD mortality than other proatherogenic measurements. Conclusions: There was a U-shape association between HDL cholesterol and CVD mortality among CAD patients. High levels of LDL cholesterol and apoB, high LDL/HDL ratio and apoB/apoA-I ratio, and low level of apoA-I were independently associated with an increased risk of CVD mortality among Chinese CAD patients.

Abstract P353: Serum Levels of Monocyte Chemoattractant Protein-1 and All-cause and Cardiovascular Mortality among Patients with Coronary Artery Disease

Serum Levels of Monocyte Chemoattractant Protein-1 and All-Cause and Cardiovascular Mortality among Patients with Coronary Artery Disease.

Diagnostic potential of urinary monocyte chemoattractant protein-1 for Alzheimer's disease and amnestic mild cognitive impairment

Characteristics, prognostic determinants of monocytes, macrophages and T cells in acute coronary syndrome: protocol for a multicenter, prospective cohort study

Monocyte Chemoattractant Protein-1, Inflammatory Biomarkers, and Prognosis of Patients With Ischemic Stroke or Transient Ischemic Attack: Fndings From a Nationwide Registry Study

The Clinical Relations among the Serum Level of Monocyte Chemoattractant Protein-1(Mcp-1) with the Severity of Coronary Atherosclerosis and Its Relationships with High Risks

The Plasma Concentration of Monocyte Chemoattractant Protein-1 and Clinical Significance in Patients with Premature Heart Disease

Abstract P268: Serum Lipids, Apolipoproteins, and Mortality among Coronary Artery Disease Patients

C-reactive Protein for Predicting Cardiovascular and All-Cause Mortality in Type 2 Diabetic Patients: A Meta-Analysis

Serum concentrations of MCP-1 and IL-6 in combination predict the presence of coronary artery disease and mortality in subjects undergoing coronary angiography

Monocyte/lymphocyte ratio as a risk factor of cardiovascular and all-cause mortality in coronary artery disease with low-density lipoprotein cholesterol levels below 1.4 mmol/L: A large longitudinal multicenter study

Body Mass Index, High-Sensitivity C-Reactive Protein and Mortality in Chinese with Coronary Artery Disease

Changes in plasma monocyte chemoattractant protein-1 in patients with acute coronary syndrome and patients with restenosis after angioplasty

Monocyte-Chemoattractant Protein-1 Levels in Human Atherosclerotic Lesions Associate With Plaque Vulnerability

Serum Lipids, Apolipoproteins, and Mortality among Coronary Artery Disease Patients.

Monocyte to high-density lipoprotein ratio is associated with mortality in patients with coronary artery diseases

Monocyte to high-density lipoprotein cholesterol ratio as long-term prognostic marker in patients with coronary artery disease undergoing percutaneous coronary intervention

Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease

Monocyte to high-density lipoprotein ratio was associated with the severity of coronary artery disease: results from a large cohort study

Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study

Peripheral Monocyte Count is an Independent Predictor of All-Cause Mortality in Type 2 Diabetes with Macro-Vascular Complications.